Evidence map›Paper›PMID 31686937›Full record

ArticleJournal of blood medicine2019

Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers.

Heba A Ahmed, Ahmed M Maklad, Safaa Aa Khaled, Ashraf Elyamany

Open access · goldAbstract read
In one paragraph

Article in Journal of blood medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Bone marrow immune cells and drug resistance in acute myeloid leukemia.Experimental biology and medicine (Maywood, N.J.) · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Decreased interleukin-35 levels and CD4Archives of medical science : AMS · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Heba A AhmedDepartment of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag, Egypt.ORCID 0000-0002-3693-0563
Ahmed M MakladDepartment of Clinical Oncology and Nuclear Medicine, Sohag University Hospitals, Sohag, Egypt.
Safaa Aa KhaledDepartment of Internal Medicine, Clinical Hematology Unit, Faculty of Medicine/Unit of Bone Marrow Transplantation, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.ORCID 0000-0002-2239-7219
Ashraf ElyamanyDepartment of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.ORCID 0000-0003-3106-9847
Assiut University · EGKing Fahd Medical City · SAKing Saud Medical City · SASohag University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesIL27 and IL35 are regulatory T cells (T-regs) related cytokines; they were accused in eukemogenesis of acute myeloid leukemia (AML). This study aimed to assess the expression of these cytokines in de novo AML and investigate their role as biomarkers. SUBJECTS AND

methodsSeventy newly diagnosed patients with primary AML and 30 matched healthy volunteers were recruited. AML diagnosis was confirmed with flowcytometric and immunophenotypic analyses, while ELISA was used to assess serum levels of IL27 and IL35 in patients and controls. Receiver operating characteristic curve analysis was used to estimate IL27 and IL35 optimum cutoff values for predicting AML.

resultsSerum levels of both cytokines were significantly higher in AML patients than controls (

conclusionConclusively, this study proved that IL27and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique we recommend the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML; however, further longitudinal research is needed to prove their exact prognostic value.

Indexed as

acute myeloid leukemia (AML)flowcytometryIL27IL35regulatory T cells

Identifiers

PMID31686937
PMCPMC6783395
OpenAlexW2977133053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.